Literature DB >> 3338350

Anovaginal and rectovaginal fistulas in Crohn's disease.

A G Radcliffe1, J K Ritchie, P R Hawley, J E Lennard-Jones, J M Northover.   

Abstract

Between 1957 and 1985, 886 women with Crohn's disease and an intact distal large bowel were seen at St. Mark's Hospital. Ninety of these patients developed a fistula between the vagina and anus or rectum at an average age of 34 years. The track of the fistula was clearly documented in 80 patients and was extrasphincteric or suprasphincteric in 36, transsphincteric in 42 (high 13, low 29), and superficial in two. Of the 90 patients, 12 (13 percent) were managed throughout without recourse to surgery. Twelve (13 percent) had the fistula laid open or drainage of an abscess as the only surgery. Twelve (13 percent) underwent repair of the fistula and, of these, eight remain symptomatically cured. One has had further symptoms but no surgery while three later underwent proctectomy for rectal disease. In eight patients the colon was removed and the rectum defunctioned and in 34 the rectum was excised as the initial surgery after development of the fistula. The remaining 12 (13 percent) underwent later proctectomy for rectal disease or failed conservative management of the fistula. Extensive colonic involvement, rectal disease, or associated anal lesions were the main reasons for rectal excision in 38 patients. In only ten was the rectovaginal fistula a prominent indication for proctectomy. As medical treatment, repair, or other local surgery were successful in one third of the patients, these options should always be considered in the first instance.

Entities:  

Mesh:

Year:  1988        PMID: 3338350     DOI: 10.1007/bf02562636

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  30 in total

1.  Analysis of function and predictors of failure in women undergoing repair of Crohn's related rectovaginal fistula.

Authors:  Galal El-Gazzaz; Tracy Hull; Emilio Mignanelli; Jeffery Hammel; Brook Gurland; Massarat Zutshi
Journal:  J Gastrointest Surg       Date:  2010-03-16       Impact factor: 3.452

Review 2.  Evaluation of perianal fistulas in patients with Crohn's disease.

Authors:  Jennifer Jones; William Tremaine
Journal:  MedGenMed       Date:  2005-05-18

3.  Recovery rates and functional results after repair for rectovaginal fistula in Crohn's disease: a comparison of different techniques.

Authors:  Sotirios Athanasiadis; Rayan Yazigi; Andreas Köhler; Christian Helmes
Journal:  Int J Colorectal Dis       Date:  2007-04-03       Impact factor: 2.571

4.  The endorectal advancement flap procedure.

Authors:  J M Stone; S M Goldberg
Journal:  Int J Colorectal Dis       Date:  1990-12       Impact factor: 2.571

5.  Rectovaginal fistulas: current surgical management.

Authors:  David E Rivadeneira; Brett Ruffo; Salim Amrani; Cynthia Salinas
Journal:  Clin Colon Rectal Surg       Date:  2007-05

6.  Endoscopic ultrasound to guide the combined medical and surgical management of pediatric perianal Crohn's disease.

Authors:  Michael J Rosen; Dedrick E Moulton; Tatsuki Koyama; Walter M Morgan; Stephen E Morrow; Alan J Herline; Roberta L Muldoon; Paul E Wise; D Brent Polk; David A Schwartz
Journal:  Inflamm Bowel Dis       Date:  2010-03       Impact factor: 5.325

7.  Rectovaginal fistulas.

Authors:  Teresa H Debeche-Adams; Jaime L Bohl
Journal:  Clin Colon Rectal Surg       Date:  2010-06

8.  Repair of a recurrent rectovaginal fistula with a biological graft.

Authors:  Kate Berger; Jonathan Faro; Sebastian Faro
Journal:  Int Urogynecol J       Date:  2015-05-05       Impact factor: 2.894

9.  An evaluation of vaginal symptoms in women with Crohn's disease.

Authors:  Deborah B Graham; Jayme R Tishon; Marie L Borum
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

10.  Treatment of anovaginal fistulas with an anocutaneous flap in patients with Crohn's disease.

Authors:  R Hesterberg; W U Schmidt; F Müller; H D Röher
Journal:  Int J Colorectal Dis       Date:  1993-03       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.